Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Oral THC and CBD in CKD
NCT05742724Phase 1Active, not recruiting
- Sponsor
- McMaster University
- Start
- Jan 2024
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dronabinol and cannabidiol, sponsored by McMaster University. Primary endpoints: Tetrahydrocannabinol and its metabolites maximum concentration at 48 hours, Tetrahydrocannabinol and its metabolites time to Cmax at 48 hours and 6 more. Started Jan 2024; status: active, not recruiting.
02
Drugs
dronabinolcannabidiol
Beyond the preview
Go deeper on NCT05742724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05742724.